InfuSystem Holdings, Inc. (AMEX: INFU) Stock Competitors & Peer Comparison
See INFU's competitors and their performance on the AMEX and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for INFU and its AMEX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INFU | $15.08 | -1.31% | 299.5M | 36.67 | $0.41 | N/A |
| ABT | $109.29 | -1.06% | 189.4B | 20.99 | $5.21 | +2.29% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $101.61 | +0.01% | 130B | 18.38 | $5.53 | +2.82% |
| SYK | $318.79 | -1.70% | 121.4B | 23.81 | $13.39 | +1.10% |
| BSX | $45.13 | +0.95% | 65.4B | 14.56 | $3.10 | N/A |
| EW | $105.81 | +1.73% | 60.9B | 39.20 | $2.70 | N/A |
| GEHC | $82.60 | -1.26% | 37.3B | 16.86 | $4.90 | +0.18% |
| DXCM | $80.35 | +0.54% | 30B | 31.51 | $2.55 | N/A |
| PHG | $30.20 | -0.69% | 29B | 17.26 | $1.75 | +3.27% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
INFU vs ABT Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, ABT has a market cap of 189.4B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while ABT trades at $109.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas ABT's P/E ratio is 20.99. In terms of profitability, INFU's ROE is +0.16%, compared to ABT's ROE of +0.09%. Regarding short-term risk, INFU is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
INFU vs BSX-PA Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, INFU's ROE is +0.16%, compared to BSX-PA's ROE of +0.14%. Regarding short-term risk, INFU is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BSX-PA's competition here
Medtronic Plc (NYSE: MDT)
INFU vs MDT Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, MDT has a market cap of 130B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while MDT trades at $101.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas MDT's P/E ratio is 18.38. In terms of profitability, INFU's ROE is +0.16%, compared to MDT's ROE of +0.11%. Regarding short-term risk, INFU is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for INFU.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
INFU vs SYK Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, SYK has a market cap of 121.4B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while SYK trades at $318.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas SYK's P/E ratio is 23.81. In terms of profitability, INFU's ROE is +0.16%, compared to SYK's ROE of +0.16%. Regarding short-term risk, INFU is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
INFU vs BSX Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, BSX has a market cap of 65.4B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while BSX trades at $45.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas BSX's P/E ratio is 14.56. In terms of profitability, INFU's ROE is +0.16%, compared to BSX's ROE of +0.14%. Regarding short-term risk, INFU is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
INFU vs EW Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, EW has a market cap of 60.9B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while EW trades at $105.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas EW's P/E ratio is 39.20. In terms of profitability, INFU's ROE is +0.16%, compared to EW's ROE of +0.10%. Regarding short-term risk, INFU is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for INFU.Check EW's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
INFU vs GEHC Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, GEHC has a market cap of 37.3B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while GEHC trades at $82.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas GEHC's P/E ratio is 16.86. In terms of profitability, INFU's ROE is +0.16%, compared to GEHC's ROE of +0.20%. Regarding short-term risk, INFU is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for INFU.Check GEHC's competition here
DexCom, Inc. (NASDAQ: DXCM)
INFU vs DXCM Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, DXCM has a market cap of 30B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while DXCM trades at $80.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas DXCM's P/E ratio is 31.51. In terms of profitability, INFU's ROE is +0.16%, compared to DXCM's ROE of +0.37%. Regarding short-term risk, INFU is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for INFU.Check DXCM's competition here
Koninklijke Philips N.V. (NYSE: PHG)
INFU vs PHG Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, PHG has a market cap of 29B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while PHG trades at $30.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas PHG's P/E ratio is 17.26. In terms of profitability, INFU's ROE is +0.16%, compared to PHG's ROE of +0.08%. Regarding short-term risk, INFU is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for INFU.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
INFU vs ZBH Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, ZBH has a market cap of 20.3B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while ZBH trades at $107.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas ZBH's P/E ratio is 12.67. In terms of profitability, INFU's ROE is +0.16%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, INFU is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
INFU vs ABMD Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas ABMD's P/E ratio is 65.36. In terms of profitability, INFU's ROE is +0.16%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, INFU is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ABMD's competition here
Glaukos Corporation (NYSE: GKOS)
INFU vs GKOS Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, GKOS has a market cap of 14.6B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while GKOS trades at $247.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas GKOS's P/E ratio is -287.42. In terms of profitability, INFU's ROE is +0.16%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, INFU is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check GKOS's competition here
Smith & Nephew plc (NYSE: SNN)
INFU vs SNN Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, SNN has a market cap of 13B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while SNN trades at $31.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas SNN's P/E ratio is 20.95. In terms of profitability, INFU's ROE is +0.16%, compared to SNN's ROE of +0.12%. Regarding short-term risk, INFU is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SNN's competition here
Penumbra, Inc. (NYSE: PEN)
INFU vs PEN Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, PEN has a market cap of 12.7B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while PEN trades at $321.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas PEN's P/E ratio is 84.01. In terms of profitability, INFU's ROE is +0.16%, compared to PEN's ROE of +0.10%. Regarding short-term risk, INFU is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
INFU vs SWAV Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas SWAV's P/E ratio is 78.76. In terms of profitability, INFU's ROE is +0.16%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, INFU is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
INFU vs ALGN Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, ALGN has a market cap of 12.1B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while ALGN trades at $172.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas ALGN's P/E ratio is 15.69. In terms of profitability, INFU's ROE is +0.16%, compared to ALGN's ROE of +0.12%. Regarding short-term risk, INFU is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ALGN's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
INFU vs BIO-B Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, BIO-B has a market cap of 10.4B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while BIO-B trades at $389.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas BIO-B's P/E ratio is -68.67. In terms of profitability, INFU's ROE is +0.16%, compared to BIO-B's ROE of +0.14%. Regarding short-term risk, INFU is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BIO-B's competition here
Insulet Corp. (NASDAQ: PODD)
INFU vs PODD Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, PODD has a market cap of 10.4B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while PODD trades at $150.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas PODD's P/E ratio is 25.56. In terms of profitability, INFU's ROE is +0.16%, compared to PODD's ROE of +0.29%. Regarding short-term risk, INFU is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for INFU.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
INFU vs BIO Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, BIO has a market cap of 10.4B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while BIO trades at $386.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas BIO's P/E ratio is 41.61. In terms of profitability, INFU's ROE is +0.16%, compared to BIO's ROE of +0.14%. Regarding short-term risk, INFU is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BIO's competition here
Globus Medical, Inc. (NYSE: GMED)
INFU vs GMED Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, GMED has a market cap of 10.1B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while GMED trades at $75.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas GMED's P/E ratio is 16.98. In terms of profitability, INFU's ROE is +0.16%, compared to GMED's ROE of +0.12%. Regarding short-term risk, INFU is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for INFU.Check GMED's competition here
Bruker Corporation (NASDAQ: BRKR)
INFU vs BRKR Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, BRKR has a market cap of 9.5B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while BRKR trades at $62.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas BRKR's P/E ratio is 31.36. In terms of profitability, INFU's ROE is +0.16%, compared to BRKR's ROE of -0.05%. Regarding short-term risk, INFU is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BRKR's competition here
Bruker Corporation (NASDAQ: BRKRP)
INFU vs BRKRP Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, BRKRP has a market cap of 9.5B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while BRKRP trades at $459.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas BRKRP's P/E ratio is 248.03. In terms of profitability, INFU's ROE is +0.16%, compared to BRKRP's ROE of -0.05%. Regarding short-term risk, INFU is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BRKRP's competition here
Masimo Corporation (NASDAQ: MASI)
INFU vs MASI Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas MASI's P/E ratio is 44.43. In terms of profitability, INFU's ROE is +0.16%, compared to MASI's ROE of +0.09%. Regarding short-term risk, INFU is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for INFU.Check MASI's competition here
Haemonetics Corporation (NYSE: HAE)
INFU vs HAE Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, HAE has a market cap of 5.5B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while HAE trades at $120.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas HAE's P/E ratio is 24.08. In terms of profitability, INFU's ROE is +0.16%, compared to HAE's ROE of +0.12%. Regarding short-term risk, INFU is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for INFU.Check HAE's competition here
LivaNova PLC (NASDAQ: LIVN)
INFU vs LIVN Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, LIVN has a market cap of 5B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while LIVN trades at $90.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas LIVN's P/E ratio is 21.61. In terms of profitability, INFU's ROE is +0.16%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, INFU is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check LIVN's competition here
Inari Medical, Inc. (NASDAQ: NARI)
INFU vs NARI Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas NARI's P/E ratio is -59.24. In terms of profitability, INFU's ROE is +0.16%, compared to NARI's ROE of -0.00%. Regarding short-term risk, INFU is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for INFU.Check NARI's competition here
Integer Holdings Corporation (NYSE: ITGR)
INFU vs ITGR Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while ITGR trades at $126.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas ITGR's P/E ratio is 19.95. In terms of profitability, INFU's ROE is +0.16%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, INFU is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ITGR's competition here
AxoGen, Inc. (NASDAQ: AXGN)
INFU vs AXGN Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, AXGN has a market cap of 3.5B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while AXGN trades at $58.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas AXGN's P/E ratio is 154.29. In terms of profitability, INFU's ROE is +0.16%, compared to AXGN's ROE of -0.11%. Regarding short-term risk, INFU is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for INFU.Check AXGN's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
INFU vs TMDX Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, TMDX has a market cap of 3.2B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while TMDX trades at $92.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas TMDX's P/E ratio is 46.71. In terms of profitability, INFU's ROE is +0.16%, compared to TMDX's ROE of +0.28%. Regarding short-term risk, INFU is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check TMDX's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
INFU vs IRTC Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, IRTC has a market cap of 2.9B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while IRTC trades at $88.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas IRTC's P/E ratio is -206.23. In terms of profitability, INFU's ROE is +0.16%, compared to IRTC's ROE of -0.23%. Regarding short-term risk, INFU is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for INFU.Check IRTC's competition here
Neogen Corporation (NASDAQ: NEOG)
INFU vs NEOG Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, NEOG has a market cap of 2.5B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while NEOG trades at $11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas NEOG's P/E ratio is 41.43. In terms of profitability, INFU's ROE is +0.16%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, INFU is more volatile compared to NEOG. This indicates higher risk in terms of short-term price fluctuations for INFU.Check NEOG's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
INFU vs UFPT Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, UFPT has a market cap of 2.4B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while UFPT trades at $314.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas UFPT's P/E ratio is 32.08. In terms of profitability, INFU's ROE is +0.16%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, INFU is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check UFPT's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
INFU vs ESTA Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, ESTA has a market cap of 2.1B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while ESTA trades at $70.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas ESTA's P/E ratio is -56.10. In terms of profitability, INFU's ROE is +0.16%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, INFU is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ESTA's competition here
NuVasive, Inc. (NASDAQ: NUVA)
INFU vs NUVA Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas NUVA's P/E ratio is 75.00. In terms of profitability, INFU's ROE is +0.16%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, INFU is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for INFU.Check NUVA's competition here
Butterfly Network, Inc. (NYSE: BFLY)
INFU vs BFLY Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, BFLY has a market cap of 1.9B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while BFLY trades at $7.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas BFLY's P/E ratio is -29.75. In terms of profitability, INFU's ROE is +0.16%, compared to BFLY's ROE of -0.28%. Regarding short-term risk, INFU is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BFLY's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
INFU vs INSP Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, INSP has a market cap of 1.8B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while INSP trades at $62.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas INSP's P/E ratio is 27.35. In terms of profitability, INFU's ROE is +0.16%, compared to INSP's ROE of +0.12%. Regarding short-term risk, INFU is more volatile compared to INSP. This indicates higher risk in terms of short-term price fluctuations for INFU.Check INSP's competition here
Enovis Corporation (NYSE: ENOV)
INFU vs ENOV Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, ENOV has a market cap of 1.6B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while ENOV trades at $28.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas ENOV's P/E ratio is 8.18. In terms of profitability, INFU's ROE is +0.16%, compared to ENOV's ROE of -0.36%. Regarding short-term risk, INFU is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ENOV's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
INFU vs LMRI Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, LMRI has a market cap of 1.5B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while LMRI trades at $15.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas LMRI's P/E ratio is -31.03. In terms of profitability, INFU's ROE is +0.16%, compared to LMRI's ROE of -0.03%. Regarding short-term risk, INFU is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check LMRI's competition here
CONMED Corporation (NYSE: CNMD)
INFU vs CNMD Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while CNMD trades at $50.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas CNMD's P/E ratio is 11.15. In terms of profitability, INFU's ROE is +0.16%, compared to CNMD's ROE of +0.07%. Regarding short-term risk, INFU is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for INFU.Check CNMD's competition here
Novocure Ltd (NASDAQ: NVCR)
INFU vs NVCR Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, NVCR has a market cap of 1.4B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while NVCR trades at $11.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas NVCR's P/E ratio is -11.31. In terms of profitability, INFU's ROE is +0.16%, compared to NVCR's ROE of -0.36%. Regarding short-term risk, INFU is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for INFU.Check NVCR's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
INFU vs PRCT Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, PRCT has a market cap of 1.3B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while PRCT trades at $23.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas PRCT's P/E ratio is -12.03. In terms of profitability, INFU's ROE is +0.16%, compared to PRCT's ROE of -0.33%. Regarding short-term risk, INFU is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check PRCT's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
INFU vs TNDM Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while TNDM trades at $18.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas TNDM's P/E ratio is -20.18. In terms of profitability, INFU's ROE is +0.16%, compared to TNDM's ROE of -0.36%. Regarding short-term risk, INFU is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for INFU.Check TNDM's competition here
Heska Corporation (NASDAQ: HSKA)
INFU vs HSKA Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas HSKA's P/E ratio is -62.49. In terms of profitability, INFU's ROE is +0.16%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, INFU is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for INFU.Check HSKA's competition here
Avanos Medical, Inc. (NYSE: AVNS)
INFU vs AVNS Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas AVNS's P/E ratio is 27.77. In terms of profitability, INFU's ROE is +0.16%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, INFU is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for INFU.Check AVNS's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
INFU vs IART Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, IART has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while IART trades at $14.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas IART's P/E ratio is 6.26. In terms of profitability, INFU's ROE is +0.16%, compared to IART's ROE of +0.01%. Regarding short-term risk, INFU is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for INFU.Check IART's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
INFU vs ATEC Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, ATEC has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while ATEC trades at $7.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas ATEC's P/E ratio is -13.07. In terms of profitability, INFU's ROE is +0.16%, compared to ATEC's ROE of -5.47%. Regarding short-term risk, INFU is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ATEC's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
INFU vs SIBN Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, SIBN has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while SIBN trades at $24.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas SIBN's P/E ratio is -73.35. In terms of profitability, INFU's ROE is +0.16%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, INFU is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SIBN's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
INFU vs SILK Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas SILK's P/E ratio is -18.96. In terms of profitability, INFU's ROE is +0.16%, compared to SILK's ROE of -0.35%. Regarding short-term risk, INFU is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SILK's competition here
IRadimed Corporation (NASDAQ: IRMD)
INFU vs IRMD Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while IRMD trades at $86.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas IRMD's P/E ratio is 43.51. In terms of profitability, INFU's ROE is +0.16%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, INFU is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for INFU.Check IRMD's competition here
Paragon 28, Inc. (NYSE: FNA)
INFU vs FNA Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas FNA's P/E ratio is -19.83. In terms of profitability, INFU's ROE is +0.16%, compared to FNA's ROE of -0.35%. Regarding short-term risk, INFU is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for INFU.Check FNA's competition here
CeriBell, Inc. (NASDAQ: CBLL)
INFU vs CBLL Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, CBLL has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while CBLL trades at $27.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas CBLL's P/E ratio is -15.61. In terms of profitability, INFU's ROE is +0.16%, compared to CBLL's ROE of -0.55%. Regarding short-term risk, INFU is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for INFU.Check CBLL's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
INFU vs AHCO Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, AHCO has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while AHCO trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas AHCO's P/E ratio is 15.92. In terms of profitability, INFU's ROE is +0.16%, compared to AHCO's ROE of -0.29%. Regarding short-term risk, INFU is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for INFU.Check AHCO's competition here
Artivion, Inc. (NYSE: AORT)
INFU vs AORT Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, AORT has a market cap of 981.5M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while AORT trades at $20.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas AORT's P/E ratio is 33.55. In terms of profitability, INFU's ROE is +0.16%, compared to AORT's ROE of -0.04%. Regarding short-term risk, INFU is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check AORT's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
INFU vs KIDS Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, KIDS has a market cap of 879.1M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while KIDS trades at $33.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas KIDS's P/E ratio is -25.13. In terms of profitability, INFU's ROE is +0.16%, compared to KIDS's ROE of -0.10%. Regarding short-term risk, INFU is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for INFU.Check KIDS's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
INFU vs CSII Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas CSII's P/E ratio is -20.83. In terms of profitability, INFU's ROE is +0.16%, compared to CSII's ROE of -0.14%. Regarding short-term risk, INFU is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for INFU.Check CSII's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
INFU vs BBNX Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, BBNX has a market cap of 801.3M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while BBNX trades at $17.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas BBNX's P/E ratio is -9.68. In terms of profitability, INFU's ROE is +0.16%, compared to BBNX's ROE of -0.27%. Regarding short-term risk, INFU is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BBNX's competition here
Picard Medical, Inc. (AMEX: PMI)
INFU vs PMI Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, PMI has a market cap of 791.8M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while PMI trades at $8.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas PMI's P/E ratio is -6.42. In terms of profitability, INFU's ROE is +0.16%, compared to PMI's ROE of -9.31%. Regarding short-term risk, INFU is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check PMI's competition here
InMode Ltd. (NASDAQ: INMD)
INFU vs INMD Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, INMD has a market cap of 790.1M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while INMD trades at $13.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas INMD's P/E ratio is 9.53. In terms of profitability, INFU's ROE is +0.16%, compared to INMD's ROE of +0.12%. Regarding short-term risk, INFU is less volatile compared to INMD. This indicates lower risk in terms of short-term price fluctuations for INFU.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
INFU vs VREX Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, VREX has a market cap of 780.9M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while VREX trades at $18.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas VREX's P/E ratio is 19.36. In terms of profitability, INFU's ROE is +0.16%, compared to VREX's ROE of +0.05%. Regarding short-term risk, INFU is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for INFU.Check VREX's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
INFU vs DCTH Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, DCTH has a market cap of 755.4M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while DCTH trades at $21.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas DCTH's P/E ratio is 2177.00. In terms of profitability, INFU's ROE is +0.16%, compared to DCTH's ROE of +0.06%. Regarding short-term risk, INFU is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for INFU.Check DCTH's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
INFU vs CTKB Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, CTKB has a market cap of 753.3M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while CTKB trades at $5.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas CTKB's P/E ratio is -30.51. In terms of profitability, INFU's ROE is +0.16%, compared to CTKB's ROE of -0.25%. Regarding short-term risk, INFU is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CTKB's competition here
Bioventus Inc. (NASDAQ: BVS)
INFU vs BVS Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, BVS has a market cap of 752.5M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while BVS trades at $10.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas BVS's P/E ratio is 14.46. In terms of profitability, INFU's ROE is +0.16%, compared to BVS's ROE of +0.27%. Regarding short-term risk, INFU is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BVS's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
INFU vs PACB Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, PACB has a market cap of 649.6M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while PACB trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas PACB's P/E ratio is -5.10. In terms of profitability, INFU's ROE is +0.16%, compared to PACB's ROE of +6.04%. Regarding short-term risk, INFU is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for INFU.Check PACB's competition here
Surmodics, Inc. (NASDAQ: SRDX)
INFU vs SRDX Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas SRDX's P/E ratio is -34.66. In terms of profitability, INFU's ROE is +0.16%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, INFU is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SRDX's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
INFU vs TCMD Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, TCMD has a market cap of 607.7M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while TCMD trades at $27.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas TCMD's P/E ratio is 25.12. In terms of profitability, INFU's ROE is +0.16%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, INFU is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for INFU.Check TCMD's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
INFU vs SGHT Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, SGHT has a market cap of 606.9M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while SGHT trades at $10.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas SGHT's P/E ratio is -19.50. In terms of profitability, INFU's ROE is +0.16%, compared to SGHT's ROE of -0.52%. Regarding short-term risk, INFU is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check SGHT's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
INFU vs AVR Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, AVR has a market cap of 604.2M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while AVR trades at $6.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas AVR's P/E ratio is -3.20. In terms of profitability, INFU's ROE is +0.16%, compared to AVR's ROE of -0.57%. Regarding short-term risk, INFU is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for INFU.Check AVR's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
INFU vs APEN Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas APEN's P/E ratio is -9.43. In terms of profitability, INFU's ROE is +0.16%, compared to APEN's ROE of -0.85%. Regarding short-term risk, INFU is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check APEN's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
INFU vs SENS Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, SENS has a market cap of 570.8M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while SENS trades at $10.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas SENS's P/E ratio is -4.67. In terms of profitability, INFU's ROE is +0.16%, compared to SENS's ROE of -1.86%. Regarding short-term risk, INFU is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check SENS's competition here
ZimVie Inc. (NASDAQ: ZIMV)
INFU vs ZIMV Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, INFU's ROE is +0.16%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, INFU is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ZIMV's competition here
Avita Medical Inc. (NASDAQ: RCEL)
INFU vs RCEL Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, RCEL has a market cap of 429.8M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while RCEL trades at $17.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas RCEL's P/E ratio is -12.01. In terms of profitability, INFU's ROE is +0.16%, compared to RCEL's ROE of +1.46%. Regarding short-term risk, INFU is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for INFU.Check RCEL's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
INFU vs NPCE Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, NPCE has a market cap of 429.7M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while NPCE trades at $12.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas NPCE's P/E ratio is -21.96. In terms of profitability, INFU's ROE is +0.16%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, INFU is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for INFU.Check NPCE's competition here
Cerus Corporation (NASDAQ: CERS)
INFU vs CERS Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, CERS has a market cap of 428.1M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while CERS trades at $2.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas CERS's P/E ratio is -70.43. In terms of profitability, INFU's ROE is +0.16%, compared to CERS's ROE of -0.11%. Regarding short-term risk, INFU is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CERS's competition here
CapsoVision, Inc. (NASDAQ: CV)
INFU vs CV Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, CV has a market cap of 333.6M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while CV trades at $6.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas CV's P/E ratio is -9.95. In terms of profitability, INFU's ROE is +0.16%, compared to CV's ROE of -1.78%. Regarding short-term risk, INFU is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CV's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
INFU vs TMCI Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, TMCI has a market cap of 331.7M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while TMCI trades at $5.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas TMCI's P/E ratio is -5.38. In terms of profitability, INFU's ROE is +0.16%, compared to TMCI's ROE of -0.76%. Regarding short-term risk, INFU is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check TMCI's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
INFU vs SMLR Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas SMLR's P/E ratio is 3.92. In terms of profitability, INFU's ROE is +0.16%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, INFU is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SMLR's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
INFU vs SSII Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, SSII has a market cap of 302.7M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while SSII trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas SSII's P/E ratio is -25.17. In terms of profitability, INFU's ROE is +0.16%, compared to SSII's ROE of -0.27%. Regarding short-term risk, INFU is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for INFU.Check SSII's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
INFU vs CLPT Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, CLPT has a market cap of 293.9M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while CLPT trades at $9.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas CLPT's P/E ratio is -7.77. In terms of profitability, INFU's ROE is +0.16%, compared to CLPT's ROE of -1.70%. Regarding short-term risk, INFU is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CLPT's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
INFU vs OFIX Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, OFIX has a market cap of 292.5M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while OFIX trades at $7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas OFIX's P/E ratio is -4.68. In terms of profitability, INFU's ROE is +0.16%, compared to OFIX's ROE of -0.10%. Regarding short-term risk, INFU is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check OFIX's competition here
Profound Medical Corp. (NASDAQ: PROF)
INFU vs PROF Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, PROF has a market cap of 287.5M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while PROF trades at $7.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas PROF's P/E ratio is -8.01. In terms of profitability, INFU's ROE is +0.16%, compared to PROF's ROE of -0.59%. Regarding short-term risk, INFU is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for INFU.Check PROF's competition here
Quantum-Si incorporated (NASDAQ: QSI)
INFU vs QSI Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, QSI has a market cap of 252.7M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while QSI trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas QSI's P/E ratio is -2.76. In terms of profitability, INFU's ROE is +0.16%, compared to QSI's ROE of -0.45%. Regarding short-term risk, INFU is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check QSI's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
INFU vs MGRM Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas MGRM's P/E ratio is -12.00. In terms of profitability, INFU's ROE is +0.16%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, INFU is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for INFU.Check MGRM's competition here
Nevro Corp. (NYSE: NVRO)
INFU vs NVRO Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas NVRO's P/E ratio is -1.91. In terms of profitability, INFU's ROE is +0.16%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, INFU is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for INFU.Check NVRO's competition here
RxSight, Inc. (NASDAQ: RXST)
INFU vs RXST Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, RXST has a market cap of 221.4M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while RXST trades at $5.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas RXST's P/E ratio is -4.67. In terms of profitability, INFU's ROE is +0.16%, compared to RXST's ROE of -0.20%. Regarding short-term risk, INFU is less volatile compared to RXST. This indicates lower risk in terms of short-term price fluctuations for INFU.Check RXST's competition here
Electromed, Inc. (AMEX: ELMD)
INFU vs ELMD Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, ELMD has a market cap of 206.9M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while ELMD trades at $24.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas ELMD's P/E ratio is 19.06. In terms of profitability, INFU's ROE is +0.16%, compared to ELMD's ROE of +0.24%. Regarding short-term risk, INFU is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ELMD's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
INFU vs BSGM Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas BSGM's P/E ratio is -5.81. In terms of profitability, INFU's ROE is +0.16%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, INFU is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BSGM's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
INFU vs MDGS Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas MDGS's P/E ratio is -0.27. In terms of profitability, INFU's ROE is +0.16%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, INFU is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
INFU vs QIPT Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas QIPT's P/E ratio is -15.87. In terms of profitability, INFU's ROE is +0.16%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, INFU is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for INFU.Check QIPT's competition here
Inogen, Inc. (NASDAQ: INGN)
INFU vs INGN Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, INGN has a market cap of 152.6M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while INGN trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas INGN's P/E ratio is -6.32. In terms of profitability, INFU's ROE is +0.16%, compared to INGN's ROE of -0.20%. Regarding short-term risk, INFU is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for INFU.Check INGN's competition here
Quanterix Corporation (NASDAQ: QTRX)
INFU vs QTRX Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, QTRX has a market cap of 142.8M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while QTRX trades at $3.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas QTRX's P/E ratio is -1.19. In terms of profitability, INFU's ROE is +0.16%, compared to QTRX's ROE of -0.43%. Regarding short-term risk, INFU is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check QTRX's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
INFU vs TLSI Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, TLSI has a market cap of 141.6M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while TLSI trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas TLSI's P/E ratio is -1.37. In terms of profitability, INFU's ROE is +0.16%, compared to TLSI's ROE of +7.60%. Regarding short-term risk, INFU is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check TLSI's competition here
Owlet, Inc. (NYSE: OWLT)
INFU vs OWLT Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, OWLT has a market cap of 134.1M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while OWLT trades at $4.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas OWLT's P/E ratio is -32.79. In terms of profitability, INFU's ROE is +0.16%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, INFU is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check OWLT's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
INFU vs FOCL Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, FOCL has a market cap of 132.3M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while FOCL trades at $3.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas FOCL's P/E ratio is -3.41. In terms of profitability, INFU's ROE is +0.16%, compared to FOCL's ROE of -2.41%. Regarding short-term risk, INFU is more volatile compared to FOCL. This indicates higher risk in terms of short-term price fluctuations for INFU.Check FOCL's competition here
Pulmonx Corporation (NASDAQ: LUNG)
INFU vs LUNG Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, LUNG has a market cap of 129.8M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while LUNG trades at $2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas LUNG's P/E ratio is -2.95. In terms of profitability, INFU's ROE is +0.16%, compared to LUNG's ROE of -0.98%. Regarding short-term risk, INFU is less volatile compared to LUNG. This indicates lower risk in terms of short-term price fluctuations for INFU.Check LUNG's competition here
Neuronetics, Inc. (NASDAQ: STIM)
INFU vs STIM Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, STIM has a market cap of 124.4M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while STIM trades at $1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas STIM's P/E ratio is -3.64. In terms of profitability, INFU's ROE is +0.16%, compared to STIM's ROE of -1.28%. Regarding short-term risk, INFU is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for INFU.Check STIM's competition here
iCAD, Inc. (NASDAQ: ICAD)
INFU vs ICAD Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas ICAD's P/E ratio is -20.37. In terms of profitability, INFU's ROE is +0.16%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, INFU is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
INFU vs HJLI Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas HJLI's P/E ratio is N/A. In terms of profitability, INFU's ROE is +0.16%, compared to HJLI's ROE of -0.70%. Regarding short-term risk, INFU is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
INFU vs ASXC Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas ASXC's P/E ratio is -1.12. In terms of profitability, INFU's ROE is +0.16%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, INFU is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ASXC's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
INFU vs CATX Comparison November 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 299.5M. In comparison, CATX has a market cap of 90M. Regarding current trading prices, INFU is priced at $15.08 on the AMEX, while CATX trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 36.67, whereas CATX's P/E ratio is -0.59. In terms of profitability, INFU's ROE is +0.16%, compared to CATX's ROE of -0.42%. Regarding short-term risk, INFU is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CATX's competition here